Janak Khimchand Padia

TL;DR: In this article, a method for treating or preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor of Formula I was proposed. But this method is not suitable for humans.

TL;DR: In this paper, the MCP-1 antagonist benzimidazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof are used in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection.

TL;DR: A novel series of CCK-B receptor antagonists is designed by combining key pharmacophores, an arylurea moiety of 1 and a quinazolinone ring of 3, from two known series by introducing -NH- as a linker, thus providing several compounds with single-digit nanomolar binding affinity and excellent selectivity.

TL;DR: The present paper relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, processes for preparing these compounds, to pharmaceutical compositions containing these compounds and methods of using these compounds for treating a wide variety of conditions and disorders.

TL;DR: A series of analogues were synthesized in which the key alpha-methyltryptophan and adamantyloxycarbonyl moieties, required for receptor binding, were kept intact and the C-terminus was extensively modified, leading to the identification of CI-1015 (31), a peptoid analogue of CCK-4 with better bioavailability and enhanced brain penetration.